论文信息 - Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients

Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients

In South Australia, between 2000 and 2014, 57 patients with idiopathic inflammatory myositis (IIM) were treated with intravenous immunoglobulin (IVIg). We reviewed disease characteristics to determine predictors of response to therapy and IVIg dosing and duration to identify opportunities to rationalise IVIg use. Patients with dermatomyositis/polymyositis had a response rate of 77% and were more likely than inclusion body myositis to respond to therapy. Consideration should be given to the use of the lowest possible dose of IVIg and to the undertaking of trials of cessation of IVIg in patients with stable IIM.

[1] C. Oddis,et al. Therapeutic advances in myositis , 2012, Current opinion in rheumatology.

[2] M. Dalakas. Inflammatory myopathies: management of steroid resistance. , 2011, Current opinion in neurology.

[3] B. Chong,et al. IVIg immune inhibitory activity: APC is key. , 2010, Blood.

[4] M. Dalakas,et al. High-dose intravenous immunoglobulin in inflammatory myopathies: experience based on controlled clinical trials , 2003, Neurological Sciences.

[5] A. Mammen,et al. Idiopathic inflammatory myopathies , 2002, Nature Reviews Disease Primers.

[6] T. Maisonobe,et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. , 2002, Arthritis and rheumatism.

[7] S. Spector,et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM , 2001, Neurology.

[8] J. Dambrosia,et al. Treatment of inclusion-body myositis with IVIg , 1997, Neurology.

[9] J. Dambrosia,et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. , 1993, The New England journal of medicine.

[10] M. Joffe,et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. , 1993, The American journal of medicine.